ClinicalTrials.gg
CompletedNCT07939659WPICAUpdated Nov 16, 2026

Warmed Povidone-Iodine Skin Antisepsis and Perioperative Comfort in Geriatric Patients Undergoing Coronary Angiography: A Randomised Controlled Trial

An interventional study of Warmed Povidone-Iodine Skin Antisepsis and Room-Temperature Povidone-Iodine Skin Antisepsis in Coronary Artery Disease, Perioperative Care and Pain, sponsored by Zonguldak Bulent Ecevit University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Zonguldak Bulent Ecevit University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Oct 2025, registered Nov 2026).
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 138 studies in Coronary Artery Disease with a site in Turkey — 33 open to participants now, 42 under way, 4 of them phase 3. Coronary Artery Disease · Turkey.

Enrollment
42nd of 72
64 · median 70
Started
2025
with 18 others
No phase
59 of 138
17 open now
Registered
138th of 138
by date

Among the 138 studies in Coronary Artery Disease with a site in Turkey, this one is the 42nd largest by enrollment of the 72 interventional ones that give a count, is one of 19 that started in 2025, is one of 59 with no phase, and was the 138th registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

33 of the 138 studies in Coronary Artery Disease with a site in Turkey are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Coronary Artery Disease with a site in Turkey, or all of them as a file.
02

Study summary

This randomised controlled trial investigated the effect of skin antisepsis performed with povidone-iodine warmed to 36°C, compared with room-temperature povidone-iodine, on perioperative comfort, pain intensity, and physiological parameters in patients aged 65 years and older undergoing elective coronary angiography. The study was conducted at the Coronary Angiography Unit of Zonguldak Atatürk State Hospital. Participants were randomly assigned to either the intervention group (warmed povidone-iodine at 36°C) or the control group (room-temperature povidone-iodine). Perioperative comfort was assessed using the Perioperative Comfort Questionnaire, pain intensity was measured using a Visual Analogue Scale, and physiological parameters including systolic and diastolic blood pressure, heart rate, respiratory rate, body temperature, and peripheral oxygen saturation were recorded at four time points: before antisepsis, immediately after antisepsis, after local anaesthetic injection, and after vascular access.

03

Conditions studied

  • Coronary Artery Disease
  • Perioperative Care
  • Pain
  • Hypothermia
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 65 years or older
  • Scheduled for elective coronary angiography
  • Able to communicate verbally
  • Willing to participate and provided written
  • No known allergy to povidone-iodine

Exclusion criteria

Exclusion Criteria:

  • Known allergy to povidone-iodine
  • Active skin infection or wound at the inguinal antisepsis site
  • Diagnosis of peripheral artery disease affecting the inguinal region
  • Use of analgesic or sedative medication within 6 hours prior to the procedure
  • Cognitive impairment precluding or self-report
  • Body temperature below 36°C or above 37.5°C at baseline
  • History of thyroid disease (due to iodine sensitivity)
  • Emergency coronary angiography
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Intervention Group

    Skin antisepsis was performed using 10% povidone-iodine solution warmed to 36°C using a solution warmer device prior to coronary angiography.

    Other: Warmed Povidone-Iodine Skin Antisepsis

  • Active comparator
    Control Group

    Skin antisepsis was performed using 10% povidone-iodine solution at room temperature (approximately 22-24°C) prior to coronary angiography.

    Other: Room-Temperature Povidone-Iodine Skin Antisepsis

Interventions

  • OtherWarmed Povidone-Iodine Skin Antisepsis

    10% povidone-iodine solution was warmed to 36°C using a solution warmer device and applied to the inguinal region prior to coronary angiography. The intervention was performed by the researcher nurse immediately before the procedure.

  • OtherRoom-Temperature Povidone-Iodine Skin Antisepsis

    10% povidone-iodine solution at room temperature (approximately 22-24°C) was applied to the inguinal region prior to coronary angiography. The intervention was performed by the researcher nurse immediately before the procedure.

06

What researchers measure

Primary outcomes

  1. Perioperative Comfort

    Perioperative comfort was assessed using the Perioperative Comfort Questionnaire (PCQ). The scale consists of 13 items rated on a 5-point Likert scale, with higher scores indicating greater comfort.

    Time frame: Assessed immediately after the coronary angiography procedure (approximately 30-45 minutes after baseline)

Secondary outcomes

  1. Pain Intensity

    Pain intensity was measured using a Visual Analogue Scale (VAS) ranging from 0 (no pain) to 10 (worst possible pain).

    Time frame: Measured at four time points: before antisepsis (baseline), immediately after antisepsis, after local anaesthetic injection, and after vascular access

  2. Systolic and Diastolic Blood Pressure

    Systolic and diastolic blood pressure measured in mmHg using a standard sphygmomanometer.

    Time frame: Measured at four time points: before antisepsis (baseline), immediately after antisepsis, after local anaesthetic injection, and after vascular access

  3. Heart Rate

    Heart rate measured in beats per minute using pulse oximetry.

    Time frame: Measured at four time points: before antisepsis (baseline), immediately after antisepsis, after local anaesthetic injection, and after vascular access

  4. Body Temperature

    Body temperature measured in degrees Celsius using a tympanic thermometer.

    Time frame: Measured at four time points: before antisepsis (baseline), immediately after antisepsis, after local anaesthetic injection, and after vascular access

  5. Peripheral Oxygen Saturation

    Peripheral oxygen saturation (SpO2) measured as a percentage using pulse oximetry.

    Time frame: Measured at four time points: before antisepsis (baseline), immediately after antisepsis, after local anaesthetic injection, and after vascular access

07

Study locations

1 site
  • Zonguldak Atatürk State Hospital
    Zonguldak, 67100, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Jan 2026, 3 months.

Of 754 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's 3 months is below that.

Counting every sponsor, half of 931 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartActual
Oct 13, 2025
Primary completionActual
Jan 15, 2026
CompletionActual
Jan 15, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939659
Responsible party
Dilek YILDIRIM TANK (Asst. Prof., Zonguldak Bulent Ecevit University) — Principal investigator
First posted
Nov 16, 2026
Start date
Oct 13, 2025
Primary completion
Jan 15, 2026
Completion
Jan 15, 2026
Last update
Nov 16, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion